By January 2025, Type 2 diabetes therapy Ozempic might be FDA approved for kidney disease-related events. 

Teva Pharmaceuticals is launching the first authorized generic of Victoza, the first generic GLP-1 product available in the United States.

GLP-1s, specifically semaglutide, had the largest effect on decreasing body mass index and maintaining weight management in children, according to a study published June 18 in JAMA Network.

Many physicians in obesity medicine have observed a trend among their patients: Those with obesity begin taking a weight loss drug like Wegovy, and their other chronic conditions improve or clear up entirely. 

Weight loss drugs were one of the most talked about topics at AHIP's June 2024 conference in Las Vegas, especially with the Amazon Pharmacy team.

Anecdotally, some people taking GLP-1s report having less cravings for more than just food.

Following jousts between Vermont Sen. Bernie Sanders and Novo Nordisk, the Senate Committee on Health, Education, Labor, and Pensions will vote June 18 on whether to subpoena the drugmaker's president about the cost of Ozempic and Wegovy. 

Kroger Health's in-store clinics are revamping the company's weight management program to include prescriptions for GLP-1s such as Wegovy and Zepbound.

Gastric emptying is a critical component to most perioperative care instructions. Now with GLP-1 medications slowing gastric emptying purposefully, researchers are racing to understand how and if the new class of drugs affects surgical procedures. 

There are only two places in the world where semaglutide (Ozempic and Wegovy) is made, and Novo Nordisk is racing against time and high demand to increase supply, Bloomberg reported May 30. 

New York City-based online, direct-to-consumer healthcare company Ro has launched a tool to report and track GLP-1 drug shortages across the U.S., it announced May 29.

Novo Nordisk is contesting Sen. Bernie Sanders' calls to reduce the list prices of Ozempic and Wegovy in the U.S., Bloomberg reports. 

In a yearslong trial of more than 3,500 participants, Novo Nordisk's Ozempic and Wegovy slowed the growth of chronic kidney disease and slashed the risk of heart attack, kidney failure, stroke and death.

Two Eli Lilly manufacturing plants in Indiana are getting a $5.3 billion boost to increase production of Zepbound and Mounjaro, the company said May 24. 

GLP-1s, a popular class of weight loss and diabetes drugs, can hinder the safety of a common gastroenterology procedure, according to a study published in Gastrointestinal Endoscopy.  

GLP-1 drugs' recent blockbuster appeal has already changed the way providers and pharmacists are doing their jobs, but the American Hospital Association says their appeal could shift other aspects of hospital operations too.

A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association.

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of responding well to GLP-1 drugs like Wegovy or Ozempic.

Weight loss drugs have the potential to bankrupt the U.S. healthcare system, according to a May 15 report from Sen. Bernie Sanders' office.

Novo Nordisk is investigating the potential of Ozempic, Wegovy's active ingredient and two other drug candidates as treatments for alcohol-related liver disease.